Skip to Content
David F Jarrard, MD

Contact Dr. Jarrard

E-mail:
jarrard@urology.wisc.edu

Phone:
(608) 262-0759

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
MADISON, WI 53705-2281

David F Jarrard, MD

Vice Chair for Clinical Affairs
Professor of Urology
John Livesey Chair in Urologic Oncology
Associate Director, UW Carbone Cancer Center

Education

  • MD, University of Virginia School of Medicine, Charlottesville, VA, 1989
  • Junior Residency in General Surgery, University of Chicago, Chicago, IL, 1989-1990
  • Residency in Urology, University of Chicago, Chicago, IL, 1990-1994
  • Fellow in Urologic Oncology, American Foundation for Urologic Disease, Johns Hopkins University, Baltimore, MD, 1994-1996

Clinical Specialties

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment including robotics.

Research Interests

Dr. Jarrard has a joint appointment with the University of Wisconsin Comprehensive Cancer Center, and his clinical research emphasizes developing novel diagnostics and new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health and Department of Defense to examine genetic and epigenetic alterations in prostate cancer.

Dr. Jarrard's lab

Funding/Grants
  • The Induction of Cellular Senescence as Therapy for Advanced Prostate Cancer
    Funding Agency: Prostate Cancer Foundation
    Principal Investigator(s): David F Jarrard, MD
    More Information

Recent Publications
  • Heninger E, Krueger TE, Thiede SM, Sperger JM, Byers BL, Kircher MR, Kosoff D, Yang B, Jarrard DF, McNeel DG, Lang JM. Inducible expression of cancer-testis antigens in human prostate cancer. Oncotarget 2016 Oct 17.
    [PubMed ID: 27769045]
    More Information
  • Blute ML, Ziemlewicz TJ, Lang JM, Kyriakopoulos C, Jarrard DF, Downs TM, Grimes M, Shi F, Mann MA, Abel EJ. Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology 2016 Sep 22.
    [PubMed ID: 27667156]
    More Information
  • Blute ML, Shiau JM, Truong M, Shi F, Abel EJ, Downs TM, Jarrard DF. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer. World J Urol 2016 Sep 15.
    [PubMed ID: 27631325]
    More Information
  • Grimes MD, Blute ML, Wittmann TA, Mann MA, Zorn K, Downs TM, Shi F, Jarrard DF, Best SL, Richards KA, Nakada SY, Abel EJ. A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology 2016 Oct; 96():93-98.
    [PubMed ID: 27339026]
    More Information
  • Kelcz F, Jarrard DF. Prostate cancer: The applicability of textural analysis of MRI for grading. Nat Rev Urol 2016 Apr; 13(4):185-6.
    [PubMed ID: 26878802]
    More Information
  • Blute ML, Zorn K, Grimes M, Shi F, Downs TM, Jarrard DF, Best SL, Richards K, Nakada SY, Abel EJ. Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU Int. 2016 Sep; 118(3):399-407.
    [PubMed ID: 26589741]
    More Information
  • Jarrard DF, Huang W. The New Age of Molecular Taxonomy Approaches. Eur. Urol. 2016 Apr; 69(4):561-2.
    [PubMed ID: 26626616]
    More Information
  • Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N. Engl. J. Med. 2015 Aug 20; 373(8):737-46.
    [PubMed ID: 26244877, PMCID: 4562797]
    More Information
  • Blute ML, Abel EJ, Downs TM, Kelcz F, Jarrard DF. Addressing the need for repeat prostate biopsy: new technology and approaches. Nat Rev Urol 2015 Aug; 12(8):435-44.
    [PubMed ID: 26171803]
    More Information
  • Blute ML, Rushmer TJ, Shi F, Fuller BJ, Abel EJ, Jarrard DF, Downs TM. Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J. Urol. 2015 Nov; 194(5):1214-9.
    [PubMed ID: 26173101]
    More Information


webmaster@surgery.wisc.edu Copyright © 2016 The Board of Regents of the University of Wisconsin System